Oscient Pharma kept by JMP at strong buy

Oscient Pharmaceuticals Corp. was maintained by JMP Securities analyst Adam Cutler at a strong buy rating with a price target on the stock of $6 per share following a weekly review of prescription data for its Factive and Testim drugs. Oscient shares Tuesday were up $0.12, or 5.13%, at $2.46 on volume of 2,104,758 shares versus the three-month running average of 777,052 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.